Cape Investment Advisory’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$141K Buy
948
+44
+5% +$6.17K 0.04% 297
2026
Q2
$114K Buy
+904
New +$119K 0.03% 320
2026
Q1
– Sell
-638
Closed -$76.5K – 585
2025
Q4
$76.5K Buy
638
+591
+1,257% +$71.8K 0.02% 342
2025
Q3
$5.22K Sell
47
-418
-90% -$47.5K 0.01% 508
2025
Q2
$51.6K Sell
465
-206
-31% -$21.9K 0.02% 363
2025
Q1
$75.2K Sell
671
-300
-31% -$31K 0.03% 287
2024
Q4
$89.7K Sell
971
-53
-5% -$4.77K 0.04% 255
2024
Q3
$85.9K Buy
1,024
+26
+3% +$1.98K 0.03% 255
2024
Q2
$68.5K Buy
998
+203
+26% +$13.5K 0.03% 260
2024
Q1
$58.2K Sell
795
-199
-20% -$15.3K 0.03% 289
2023
Q4
$80.5K Buy
994
+101
+11% +$7.86K 0.04% 265
2023
Q3
$66.9K Hold
893
– – 0.04% 253
2023
Q2
$68.8K Buy
893
+1
+0.1% +$80 0.04% 245
2023
Q1
$74K Buy
+892
New +$73.9K 0.05% 219

Other funds holding GILD

Cape Investment Advisory's GILD Position: Q3 2026 in Review

Cape Investment Advisory increased its Gilead Sciences (GILD) stake by 4.9% in Q3 2026, buying an estimated $6.17K and bringing the position to 948 shares worth $141K. The position accounts for 0.04% of the portfolio, ranked #297.

Cape Investment Advisory first reported a position in GILD in Q1 2023 and has held it in 14 quarters since. 266 funds tracked by Wall St. Rank hold GILD as of Q3 2026.

  • Cape Investment Advisory held 948 shares of Gilead Sciences worth $141K as of Q3 2026.
  • Cape Investment Advisory bought 44 Gilead Sciences shares in Q3 2026, an estimated $6.17K.
  • Gilead Sciences made up 0.04% of Cape Investment Advisory's portfolio in Q3 2026, its #297 holding.
  • Cape Investment Advisory first reported a position in Gilead Sciences in Q1 2023 and has held it in 14 quarters since.
  • 266 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.

Based on Cape Investment Advisory's 13F filing for Q3 2026, filed 13 Oct 2026.